Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
3 Top Breakout Stocks to Invest in for Excellent Returns
08:14am, Thursday, 03'rd Aug 2023
First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today.
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
07:00am, Monday, 31'st Jul 2023
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at 8:
Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug
12:06pm, Wednesday, 28'th Jun 2023
Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.
Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?
12:42pm, Friday, 09'th Jun 2023
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus Therapeutics: Finally The FDA Inspection Is Done, Time To Be Positive
04:25pm, Monday, 22'nd May 2023
The FDA inspected the WuXi facility this month, and Amicus Therapeutics, Inc. expects approval in the third quarter. Galafold revenue is growing, although the ANDA challenge needs to be resolved.
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow
09:10am, Thursday, 11'th May 2023
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates.
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
09:56am, Wednesday, 10'th May 2023
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.30 per share a year ago.
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
07:00am, Monday, 01'st May 2023
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:3
These Are the Top 10 Holdings of Avoro Capital Advisors
10:54pm, Monday, 17'th Apr 2023
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
02:45pm, Friday, 14'th Apr 2023
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe
12:15pm, Tuesday, 28'th Mar 2023
Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).
Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates
11:18am, Wednesday, 01'st Mar 2023
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -46.15% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
07:00am, Monday, 27'th Feb 2023
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference i
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
07:00am, Tuesday, 14'th Feb 2023
PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
07:00am, Wednesday, 08'th Feb 2023
PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference
